REG - Oxford BioDynamics - Result of AGM

Oxford BiodynamicsAnnouncement

27/03/2024 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240327:nRSa5635Ia&default-theme=true

RNS Number : 5635I  Oxford BioDynamics PLC  27 March 2024

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Result of AGM

27 March 2024 - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a
biotechnology company developing precision medicine tests based on the
EpiSwitch® 3D genomics platform announces that all resolutions proposed at
the Company's Annual General Meeting, held earlier today, were duly passed.

 

For further details please contact:

 Oxford BioDynamics Plc                            +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser and Broker      +44 (0)20 7408 4090

 Advisory: Stephane Auton / Iain Sexton

 Broking: Fiona Conroy

 WG Partners - Joint Broker                        +44 (0)20 3705 9330

 David Wilson / Claes Spång / Sateesh Nadarajah

/ Erland Sternby

 Instinctif Partners                               +44 (0)20 7457 2020
 Melanie Toyne-Sewell / Jack Kincade               OxfordBioDynamics@instinctif.com

 

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
 (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86N2M0NzFjODkyYjNjY2ExNGFhYzMzMDE5Mjc2MTEyOWU6Njo3MGRmOmQ2ODk5YjcwZjliODIwNDdhNjZmM2Q5ZTRhMzcwMTM1OWJjZjI1ZTdjNDJmYTRmNDNhMDgxYmIyZTBhZGNmNTU6cDpG)
 (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune
response profile for immuno-oncology (IO) checkpoint inhibitor treatments,
launched in February 2022. PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer, which was launched in the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic
test, EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
 (Covid Severity Test) and the first commercially available microarray kit
for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.

For more information, please visit the Company's
website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
 (@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUBASRSNUOUAR